Pfizer plunges over 4% as it scraps obesity pill trials



The shares of Pfizer Inc. tumbled more than 4% on Monday following the news the pharma giant decided to halt the development of its experimental obesity pill lotiglipron.

Ahead of the session, Pfizer…

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento